INSP

Business Context and Reporting Period

Company: Inspire Medical Systems, Inc. (INSR)

Filing Type: Form 10-Q (Quarterly Report)

Reporting Period: Three months ended March 31, 2026

Business Overview: Inspire Medical Systems develops and commercializes the Inspire system, a neurostimulation therapy for moderate to severe obstructive sleep apnea (OSA). The company operates as a single segment, selling primarily in the U.S. and select international markets.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 1.6% year-over-year, driven by growth in both U.S. and International regions. U.S. growth was partially offset by coding/reimbursement challenges and the WISeR program.
• Profitability Shift: The company reported a net loss of $11.3 million compared to net income of $3.0 million in the prior year. This reversal was primarily due to a significant increase in income tax expense.
• Tax Expense Spike: Income tax expense rose to $13.7 million (effective rate 571.2%) from $1.2 million (28.1%). This was driven by stock-based compensation tax shortfalls due to a decline in stock price at vesting/exercise compared to grant-date fair value.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 5.5% to $152.2 million due to higher payroll, marketing, and legal fees. R&D expenses decreased 7.1% to $25.8 million.
• Cash Flow: Operating cash flow improved significantly to $12.8 million provided, compared to $6.7 million used in the prior year, driven by improved working capital management.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Reimbursement Uncertainty: Significant uncertainty remains regarding coding and reimbursement for the Inspire V therapy. The American Hospital Association recommended CPT code 64999 (unlisted procedure), which may increase claims review time. CMS implemented new HCPCS C-codes for facility billing in April 2026. Management anticipates these issues will continue to adversely impact revenue throughout 2026.
• WISeR Program: The Wasteful and Inappropriate Service Reduction (WISeR) program, requiring prior authorization in six pilot states, began in January 2026 and has caused revenue delays.
• GLP-1 Impact: The increasing adoption of GLP-1 drugs for weight loss and OSA is currently adversely impacting short-term revenue as some physicians prescribe these drugs before considering Inspire therapy. However, management believes long-term eligibility may increase as patients reduce BMI into the Inspire indication range.
• Commercial Organization: The company is optimizing its sales model with territory consolidation and increased field clinical representatives (288 FCRs as of March 31, 2026).

Risks and Contingencies

• Legal Proceedings:
  • Securities Class Actions: A putative securities class action (Indiana PRS Lawsuit) regarding the Inspire V launch is pending. A previous similar suit (City of Pontiac) was dismissed. Two derivative lawsuits (Korte and Davis) have been filed and are proposed to be consolidated.
  • Government Investigation: The DOJ issued a Civil Investigative Demand (CID) in January 2025 regarding potential False Claims Act violations related to marketing and reimbursement practices.
  • Patent Litigation: Ongoing patent disputes with Nyxoah SA regarding infringement claims in the U.S. and Unified Patent Court.
• Seasonality: Q1 is historically a slower period due to the reset of patient insurance deductibles.

Investor Verification Checklist

• Reimbursement Resolution: Monitor updates on CPT code 64999 adoption and CMS/MAC guidance for Inspire V to assess revenue headwinds.
• GLP-1 Market Dynamics: Track physician prescribing patterns regarding GLP-1s versus Inspire therapy to validate long-term demand projections.
• Legal Exposure: Review developments in the Indiana PRS securities lawsuit and the DOJ False Claims Act investigation for potential financial liabilities.
• Tax Rate Normalization: Verify if the 571.2% effective tax rate is a one-time Q1 anomaly due to stock price volatility or indicative of a structural change.
• Inventory Levels: Note the increase in inventory to $166.2 million (up from $145.3 million) and monitor for potential write-downs if sales slow due to reimbursement delays.